Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as
docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) together with cetuximab may kill more tumor cells.
PURPOSE: This phase II clinical trial is studying how well cetuximab given together with
combination chemotherapy works in treating patients with stage III or stage IV oropharynx
cancer that can be removed by surgery.
Phase:
Phase 2
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)